Riskpilot← Back to searchSign inGet full accessPharmaxim Holding AB
ABActiveOrg 5591339394StockholmActivities of head offices · NACE 7010Est. 20170 employees
Revenue 2024
SEK 100K
0% vs 2023
EBITDA margin
-30.0%
+92% vs 2023
Equity ratio
65.6%
Financial strength
Net profit 2024
SEK 2,5M
0 employees
| Revenue | SEK 100K | +0% |
| EBITDA | SEK -30K | +92% |
| Net profit | SEK 2,5M | — |
| Total assets | SEK 88,4M | +2% |
| Equity | SEK 58M | +4% |
| Employees | 0 | — |
Legal name
Pharmaxim Holding AB
Org number
5591339394
Legal form
Aktiebolag
NACE code
7010 · Activities of head offices
Founded
15 november 2017
Share capital
SEK 61 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna
Company purpose
Aktiebolaget ska äga och förvalta aktier samt bedriva därmed förenlig verksamhet.
Address
Stockholm
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 100 | 100 | 100 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −156 | −4 | −65 | −386 | −30 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −156 | −4 | −65 | −386 | −30 |
| Net financials | 11 495 | 9 638 | −96 | −49 | −311 |
| Profit before tax | 11 338 | 9 634 | 6 920 | 24 | 3 153 |
| Tax | −0 | −0 | −1 221 | −24 | −679 |
| Net profit | 11 338 | 9 634 | 5 699 | 0 | 2 474 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 77 690 | 79 105 | 84 844 | 86 300 | 88 434 |
| Equity | 40 790 | 50 424 | 56 123 | 55 821 | 57 974 |
| Long-term debt | 0 | 0 | 8 270 | 21 340 | 17 031 |
| Short-term debt | 25 131 | 16 911 | 6 706 | 5 394 | 8 585 |
| Total debt | 25 131 | 16 911 | 14 976 | 26 734 | 25 616 |
EBITDA margin
-30.0%
This company
15.8%
Market median
-290% vs market
20202024
Equity ratio
65.6%
This company
38.2%
Market median
+72% vs market
20202024
Return on equity
4.3%
This company
18.4%
Market median
-77% vs market
20202024
Net profit margin
2474.0%
This company
8.1%
Market median
+30443% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.53×
This company
0.62×
Market median
+15% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
HN Chief Auditor | Chief Auditor | 2020 |
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Board of Directors | 2020 | |
| Chairman | 2020 | |
| Board of Directors | 2020 | |
| Board of Directors | 2021 | |
| Former (2) | ||
| Board of Directors | 2020 – 2021 | |
| Deputy Board Member | 2020 – 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 94% | 94% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
CeHa Holding AB
Pharmaxim Holding AB Board members of Pharmaxim Holding AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Henrik Nils Gunnar Boman | Chief Auditor | 0 companies |
| Nils Johan Cederlund | Board of Directors | 0 companies |
| Måns Wicktor Nermark | Chairman | 0 companies |
| Christian Henrik Hoffmann | Board of Directors | 0 companies |
| Ove Kurt Ohlson | Board of Directors | 0 companies |
| Ernst Anders Christer Bengtsson | Deputy Board Member | 0 companies |
| Johan Patrik Bäckström | Board of Directors | 0 companies |